Navigation Links
PSA Testing Linked to Improved Prostate Cancer Survival
Date:8/23/2012

THURSDAY, Aug. 23 (HealthDay News) -- Prostate cancer survival rates in the United States have improved since the introduction of prostate-specific antigen (PSA) testing, researchers report.

PSA is a protein released into the body by the prostate gland. PSA screening involves measuring the amount of PSA in a man's blood. The higher the PSA level, the more likely it is that a man has prostate cancer.

The new study, published Aug. 23 in The Journal of Urology, found that routine use of PSA testing for prostate cancer screening and monitoring has resulted in earlier and more sensitive detection of the disease. This has led to improved survival for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body ("metastatic prostate cancer").

In addition, the survival rate for black patients has improved and is now about the same as for whites, the investigators found.

For the study, researchers analyzed data from three clinical trials conducted over the last three decades that evaluated patient survival after androgen (hormone)-deprivation treatment for prostate cancer. Two of the clinical trials were conducted before the introduction of PSA screening, and one took place after.

Median survival was 30 months in the first trial (conducted from 1985 to 1986), 33 months in the second trial (conducted from 1989 to 1994), and 49 months in the third trial (conducted from 1995 to 2009). Patients in the most recent trial also had a 30 percent decreased risk of death, the study found.

Among black patients, median survival was 27 months in the first trial and 48 months in the third trial, which is close to that of white patients, the study authors noted in a journal news release.

This improvement in black patients' survival may be due to greater awareness of prostate cancer and increased likelihood that they will seek health care, suggested lead investigator Dr. Ian Thompson, director of the Cancer Therapy and Research Center, a U.S. National Cancer Institute-designated cancer center, and a professor in the urology department at the University of Texas Health Science Center at San Antonio.

However, Thompson noted that black men have a twofold to threefold greater incidence of newly diagnosed metastatic prostate cancer than white men, which contributes to a similarly higher death rate. This shows the need for a greater effort to eliminate disparities in prostate cancer, he pointed out in the news release.

While not all of the improvements in prostate cancer survival "can be attributed strictly to PSA testing, without a doubt it has played a role in extending many lives," Thompson concluded.

PSA testing has been controversial.

In May, the U.S. Preventive Services Task Force recommended against routine PSA screening, saying too many non-dangerous cancers were being treated aggressively and resulting in unnecessary harm.

But a July study in the journal Cancer found that not screening American men would triple the number developing advanced cancer, and the American Society of Clinical Oncology recommended that men with a life expectancy of more than 10 years talk with their doctors about getting the test.

While the new study uncovered an association between routine PSA testing and improved rates of prostate cancer survival, it did not prove a cause-and-effect relationship.

More information

The U.S. National Cancer Institute has more about PSA testing.

-- Robert Preidt

SOURCE: The Journal of Urology, news release, Aug. 23, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Sensor detects glucose in saliva and tears for diabetes testing
2. Prostate cancer survival rates improved since introduction of PSA testing
3. HIV home testing kits prove their worth
4. By studying animal health, researchers find improved ways for developing, testing cancer therapies
5. Heterogeneous ER+ breast cancer models allow more accurate drug testing
6. What would happen without PSA testing?
7. HPV testing in HIV-positive women may help reduce frequent cervical cancer screening
8. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
9. Wednesday Is National HIV Testing Day
10. Experts recommend men at risk for osteoporosis undergo bone density testing
11. Guidelines Issued for When Docs Should Order Vascular Testing
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PSA Testing Linked to Improved Prostate Cancer Survival
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
Breaking Medicine Technology: